Modality
Bispecific Ab
MOA
C5i
Target
CD19
Pathway
Notch
Cholangiocarcinoma
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Jan 2027
Phase 2Current
NCT04904861
1,672 pts·Cholangiocarcinoma
2021-08→2027-01·Recruiting
1,672 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-099mo awayPh3 Readout· Cholangiocarcinoma
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-01-09 · 9mo away
Cholangiocarcinoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04904861 | Phase 2/3 | Cholangiocarcinoma | Recruiting | 1672 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| VYG-2926 | Voyager | NDA/BLA | CD19 | |
| SDG-1247 | Schrodinger | Phase 1 | CD19 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |